Stocktoria
10x Genomics, Inc. TXG
10x Genomics, Inc. (TXG) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $642.8M at a -6.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.54 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-01 | Piper Sandler | Neutral (main) |
| 2026-06-24 | Barclays | Overweight (main) |
| 2026-05-12 | Morgan Stanley | Equal-Weight (main) |
| 2026-05-12 | JP Morgan | Neutral (main) |
| 2026-04-20 | Canaccord Genuity | Buy (main) |
| 2026-04-20 | B of A Securities | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.51 |
| Retained earnings / assets | -1.451 |
| EBIT / assets | -0.059 |
| Equity / liabilities | 3.25 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TXG | 10x Genomics, Inc. | 4/9 | 1.63 | — | +5.2% |
| CTKB | Cytek Biosciences, Inc. | 3/9 | 6.15 | — | +0.5% |
| PACB | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 3/9 | -13.42 | — | +3.9% |
| QTRX | Quanterix Corp | 1/9 | -1.83 | — | +1.1% |
| HBIO | HARVARD BIOSCIENCE INC | 4/9 | -10.45 | — | -8.1% |
| PRPO | Precipio, Inc. | 7/9 | -13.13 | — | +28% |
| RPID | RAPID MICRO BIOSYSTEMS, INC. | 2/9 | — | — | +19.7% |
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
FAQ
Is TXG financially healthy?
10x Genomics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does TXG pay a dividend?
No, 10x Genomics, Inc. does not currently pay a dividend.
How profitable is TXG?
In FY2025, 10x Genomics, Inc. had a net margin of -6.8% and a return on equity of -5.5%.
What is the analyst price target for TXG?
The average Wall-Street price target for 10x Genomics, Inc. is $27.62, about 52.2% below the recent price, from 13 analysts (consensus: buy).
Is TXG a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on 10x Genomics, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.